Cellular implantation for the treatment of chronic pain

Jacqueline Sagen, Mary Eaton

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Although narcotic analgesics and fonnulations containing opioids are the most commonly used agents for the treatment of moderate to severe pain, the use of exogenous drug administration on a long-tenn basis for chronic pain management is often not optimal owing to potentially serious or disturbing side effects, tolerance development, poor pain control, and inconvenience. Over the last two decades, the field of cellular transplantation has exploded as a potential means of providing a local and continually renewable supply of therapeutic molecules. Cell therapy that uses transplants of cells from primary tissue, such as adrenal medullary chromaffin cells, or immortalized, bioengineered cell lines that secrete pain-reducing neuroactive substances into the central nervous system (CNS), offers a feasible alternative in the long-tenn management of chronic pain. Similar to the more common drug pumps used for opioid delivery, cellular implants permit long-tenn, low, local dose delivery of antinociceptive agents into the cerebrospinal fluid (CSP), without the side effects associated with large doses or systemic administration. In addition, these biological “cellular minipumps” permit the delivery and utilization of molecules that have biological half-lives that are too short to allow them to be delivered by other means, such as osmotic pumps with intrathecal catheters. With continued viability, cell transplants avoid the problems of catheter-related infections, refilling, and maintenance required with the drug pumps. Although, to date, primary cells have been utilized in initial clinical pain trials, one can envision the possibilities of generating cell lines that can manufacture novel analgesic agents for specific pain indications, or respond to the physiological microenvironment by bioengineering cells to secrete agents only when they are needed, such as with periodic episodes of pain. Some of these pain-reducing neuroactive substances that could be manufactured by the cellular minipumps include opioid peptides (e.g., endorphins and enkephalins) and other peptides such as galanin, neurotensin, somatostatin, and calcitonin; neurotransmitters such as norepinephrine, epinephrine, serotonin, and y-arninobutyric acid (GABA); neurotrophins such as brain-derived neurotrophic factor (BDNF); cytokines such as interleukin (lL)-lO, and numerous other neuroactive molecules, the genes of which can be introduced into bioengineered cell lines.

Original languageEnglish (US)
Title of host publicationPain
Subtitle of host publicationCurrent Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery
PublisherCRC Press
Pages815-833
Number of pages19
ISBN (Electronic)9780203911259
ISBN (Print)0824788656, 9780824788650
StatePublished - Jan 1 2003

Fingerprint

Chronic Pain
Pain
Cell Line
Opioid Analgesics
Therapeutics
Analgesics
Pharmaceutical Preparations
Endorphins
Transplants
Cellular Microenvironment
Galanin
Catheter-Related Infections
Bioengineering
Neurotensin
Chromaffin Cells
Opioid Peptides
Enkephalins
Interleukins
Brain-Derived Neurotrophic Factor
Narcotics

ASJC Scopus subject areas

  • Health Professions(all)
  • Medicine(all)

Cite this

Sagen, J., & Eaton, M. (2003). Cellular implantation for the treatment of chronic pain. In Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery (pp. 815-833). CRC Press.

Cellular implantation for the treatment of chronic pain. / Sagen, Jacqueline; Eaton, Mary.

Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. CRC Press, 2003. p. 815-833.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sagen, J & Eaton, M 2003, Cellular implantation for the treatment of chronic pain. in Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. CRC Press, pp. 815-833.
Sagen J, Eaton M. Cellular implantation for the treatment of chronic pain. In Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. CRC Press. 2003. p. 815-833
Sagen, Jacqueline ; Eaton, Mary. / Cellular implantation for the treatment of chronic pain. Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. CRC Press, 2003. pp. 815-833
@inbook{6ff13653cb6040ccae54859b2696a1f2,
title = "Cellular implantation for the treatment of chronic pain",
abstract = "Although narcotic analgesics and fonnulations containing opioids are the most commonly used agents for the treatment of moderate to severe pain, the use of exogenous drug administration on a long-tenn basis for chronic pain management is often not optimal owing to potentially serious or disturbing side effects, tolerance development, poor pain control, and inconvenience. Over the last two decades, the field of cellular transplantation has exploded as a potential means of providing a local and continually renewable supply of therapeutic molecules. Cell therapy that uses transplants of cells from primary tissue, such as adrenal medullary chromaffin cells, or immortalized, bioengineered cell lines that secrete pain-reducing neuroactive substances into the central nervous system (CNS), offers a feasible alternative in the long-tenn management of chronic pain. Similar to the more common drug pumps used for opioid delivery, cellular implants permit long-tenn, low, local dose delivery of antinociceptive agents into the cerebrospinal fluid (CSP), without the side effects associated with large doses or systemic administration. In addition, these biological “cellular minipumps” permit the delivery and utilization of molecules that have biological half-lives that are too short to allow them to be delivered by other means, such as osmotic pumps with intrathecal catheters. With continued viability, cell transplants avoid the problems of catheter-related infections, refilling, and maintenance required with the drug pumps. Although, to date, primary cells have been utilized in initial clinical pain trials, one can envision the possibilities of generating cell lines that can manufacture novel analgesic agents for specific pain indications, or respond to the physiological microenvironment by bioengineering cells to secrete agents only when they are needed, such as with periodic episodes of pain. Some of these pain-reducing neuroactive substances that could be manufactured by the cellular minipumps include opioid peptides (e.g., endorphins and enkephalins) and other peptides such as galanin, neurotensin, somatostatin, and calcitonin; neurotransmitters such as norepinephrine, epinephrine, serotonin, and y-arninobutyric acid (GABA); neurotrophins such as brain-derived neurotrophic factor (BDNF); cytokines such as interleukin (lL)-lO, and numerous other neuroactive molecules, the genes of which can be introduced into bioengineered cell lines.",
author = "Jacqueline Sagen and Mary Eaton",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
isbn = "0824788656",
pages = "815--833",
booktitle = "Pain",
publisher = "CRC Press",

}

TY - CHAP

T1 - Cellular implantation for the treatment of chronic pain

AU - Sagen, Jacqueline

AU - Eaton, Mary

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Although narcotic analgesics and fonnulations containing opioids are the most commonly used agents for the treatment of moderate to severe pain, the use of exogenous drug administration on a long-tenn basis for chronic pain management is often not optimal owing to potentially serious or disturbing side effects, tolerance development, poor pain control, and inconvenience. Over the last two decades, the field of cellular transplantation has exploded as a potential means of providing a local and continually renewable supply of therapeutic molecules. Cell therapy that uses transplants of cells from primary tissue, such as adrenal medullary chromaffin cells, or immortalized, bioengineered cell lines that secrete pain-reducing neuroactive substances into the central nervous system (CNS), offers a feasible alternative in the long-tenn management of chronic pain. Similar to the more common drug pumps used for opioid delivery, cellular implants permit long-tenn, low, local dose delivery of antinociceptive agents into the cerebrospinal fluid (CSP), without the side effects associated with large doses or systemic administration. In addition, these biological “cellular minipumps” permit the delivery and utilization of molecules that have biological half-lives that are too short to allow them to be delivered by other means, such as osmotic pumps with intrathecal catheters. With continued viability, cell transplants avoid the problems of catheter-related infections, refilling, and maintenance required with the drug pumps. Although, to date, primary cells have been utilized in initial clinical pain trials, one can envision the possibilities of generating cell lines that can manufacture novel analgesic agents for specific pain indications, or respond to the physiological microenvironment by bioengineering cells to secrete agents only when they are needed, such as with periodic episodes of pain. Some of these pain-reducing neuroactive substances that could be manufactured by the cellular minipumps include opioid peptides (e.g., endorphins and enkephalins) and other peptides such as galanin, neurotensin, somatostatin, and calcitonin; neurotransmitters such as norepinephrine, epinephrine, serotonin, and y-arninobutyric acid (GABA); neurotrophins such as brain-derived neurotrophic factor (BDNF); cytokines such as interleukin (lL)-lO, and numerous other neuroactive molecules, the genes of which can be introduced into bioengineered cell lines.

AB - Although narcotic analgesics and fonnulations containing opioids are the most commonly used agents for the treatment of moderate to severe pain, the use of exogenous drug administration on a long-tenn basis for chronic pain management is often not optimal owing to potentially serious or disturbing side effects, tolerance development, poor pain control, and inconvenience. Over the last two decades, the field of cellular transplantation has exploded as a potential means of providing a local and continually renewable supply of therapeutic molecules. Cell therapy that uses transplants of cells from primary tissue, such as adrenal medullary chromaffin cells, or immortalized, bioengineered cell lines that secrete pain-reducing neuroactive substances into the central nervous system (CNS), offers a feasible alternative in the long-tenn management of chronic pain. Similar to the more common drug pumps used for opioid delivery, cellular implants permit long-tenn, low, local dose delivery of antinociceptive agents into the cerebrospinal fluid (CSP), without the side effects associated with large doses or systemic administration. In addition, these biological “cellular minipumps” permit the delivery and utilization of molecules that have biological half-lives that are too short to allow them to be delivered by other means, such as osmotic pumps with intrathecal catheters. With continued viability, cell transplants avoid the problems of catheter-related infections, refilling, and maintenance required with the drug pumps. Although, to date, primary cells have been utilized in initial clinical pain trials, one can envision the possibilities of generating cell lines that can manufacture novel analgesic agents for specific pain indications, or respond to the physiological microenvironment by bioengineering cells to secrete agents only when they are needed, such as with periodic episodes of pain. Some of these pain-reducing neuroactive substances that could be manufactured by the cellular minipumps include opioid peptides (e.g., endorphins and enkephalins) and other peptides such as galanin, neurotensin, somatostatin, and calcitonin; neurotransmitters such as norepinephrine, epinephrine, serotonin, and y-arninobutyric acid (GABA); neurotrophins such as brain-derived neurotrophic factor (BDNF); cytokines such as interleukin (lL)-lO, and numerous other neuroactive molecules, the genes of which can be introduced into bioengineered cell lines.

UR - http://www.scopus.com/inward/record.url?scp=5644256580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644256580&partnerID=8YFLogxK

M3 - Chapter

SN - 0824788656

SN - 9780824788650

SP - 815

EP - 833

BT - Pain

PB - CRC Press

ER -